Influenza viruses belong to the family Orthomyxoviridae and have a single-stranded segmented RNA genome. The influenza viruses are classified into types A, B, and C on the basis of their core proteins. Type A viruses are further subdivided according to their envelope glycoproteins with haemagglutinin (HA) or neuraminidase (NA) activity. Characteristic of many RNA genome viruses, influenza virus undergoes high mutation rates and frequent genetic reassortment (combination and rearrangement of genetic material) leading to variability in HA and NA antigens. Minor changes in the protein structure in influenza A strains ("antigenic drift") occur frequently, enabling the virus to cause repetitive influenza outbreaks by evading immune recognition. Major changes in the influenza type A HA antigen ("antigenic shift") are caused by reassortment from different influenza A subtypes, such as between animal and human subtypes, and in rare events, such shifted viruses can result in strains capable of causing large regional or global pandemic outbreaks. Influenza B and C viruses mainly affect humans, whereas influenza A viruses infect a range of mammalian and avian species. Only type A and B cause human disease of any concern.
Influenza virus is transmitted primarily by droplets or respiratory secretions of infected persons. Influenza occurs all over the world, with an annual global attack rate estimated at 5 – 10% in adults and 20 – 30% in children. Influenza is associated with considerable economic burden arising from health-care costs, lost days of work or education, and general social disruption across all age groups. Secondary bacterial pneumonia is a frequent complication of influenza infection, particularly in elderly people and individuals with certain chronic diseases, resulting in a significant level of morbidity and mortality. An influenza pandemic is a rare but recurrent event.
Protection against clinical disease is mainly conferred by serum antibodies, whereas mucosal IgA antibodies contribute to resistance against infection. HA is the major antigenic target of neutralizing antibodies. However, due to antigenic drift and antigenic shift, the protective effect of antibody induced by one strain may be reduced or lost as a function of time, resulting in individuals being relatively or completely unprotected against the new strains in circulation.
The World Health Organization reviews the world epidemiological situation twice annually and if necessary recommends new vaccine strain(s) in accordance with the available evidence. In general, seasonal influenza vaccines are trivalent, containing a mixture of influenza A and B strains thought most likely to circulate in the coming season. However, monovalent vaccines have been produced against candidate pandemic strains. It is now common practice to use reassortant strains for production that give high yields of the appropriate surface antigens. Reassortant strains for vaccine production have the surface glycoproteins (HA and NA) of the circulating epidemic virus but the internal proteins of a standardized production strain, eliminating much of the risks associated with handling pathogenic strains. The virus is grown in chick embryos or cell cultures for the production of vaccines. Due to the need to rapidly manufacture new vaccines in response to the likely strains that are identified, a unique set of regulatory requirements must be applied to the development, testing, and batch release of both seasonal and pandemic response influenza vaccines. Two types of influenza vaccine are available, an inactivated (killed) preparation that is injected and an attenuated influenza vaccine normally delivered nasally.
There are three types of inactivated vaccines, the whole virus vaccines, split virus vaccines, and subunit vaccines. In split virus vaccines, the virus has been disrupted by a detergent. In subunit vaccines, HA and NA have been further purified by removal of other viral components. Some formulations include adjuvants and most multidose vials contain the preservative thiomersal. Live, attenuated influenza vaccines have been based on a temperature-sensitive variant vaccine virus strains that replicate well in the nasopharynx but poorly in the lower respiratory tract.
Influenza Vaccine Standardization
WHO recommendations for the production and quality control of inactivated influenza vaccines were first developed in 1967 and subsequently revised in 1978, 1990 and 2003. The most recent revision takes into consideration the use of mammalian cells for production, the use of adjuvants, the development of reverse genetics for the generation of vaccine viruses, and increased levels of pandemic planning.
Recommendations for the production and control of influenza vaccine (inactivated), WHO Technical Report Series No. 927, Annex 3
Addendum to: Annex 3 of WHO Technical Report Series, No. 927 - Labelling information of inactivated influenza vaccines for use in pregnant women, TRS 1004, Annex 8
Live attenuated vaccines
WHO recommendations for the production and quality control of live attenuated influenza vaccines were formulated in 1978 to take into account the increased interest in immunization using live attenuated viruses introduced by the natural mode of infection. These recommendations were subsequently revised and adopted by the ECBS at their 60th meeting in 2009.
WHO recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration, Technical Report Series, 977, Annex 4
Due to the inherent risks in handling pandemic influenza strains for the production of vaccines where an uncontrolled release could have a significant public health impact, a detailed risk assessment for pandemic influenza production strains and the biosafety precautions needed in manufacturing environments. WHO issued a biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines in 2005. These guidelines cover biosafety aspects of pandemic influenza vaccines produced from wild strains, attenuated (reassortment) strains, and live attenuated strains. The document was updated to include the pandemic influenza A (H1N1) virus in 2009. This update is relevant to both vaccine development and production activities.
Guidance to provide National Regulatory Authorities (NRAs) and vaccine manufacturers with state-of-the-art advice concerning regulatory pathways for pandemic influenza vaccines, regulatory considerations to take into account in evaluating the quality, safety and efficacy of vaccine candidates and requirements for effective post-marketing surveillance of pandemic influenza vaccines were endorsed by ECBS in 2007.
Generic protocol for the calibration of seasonal and pandemic influenza antigen working reagents by WHO essential regulatory laboratories, TRS 979, Annex 5
Regulatory preparedness for human pandemic influenza vaccines, TRS 963, Annex 2
Guidelines on regulatory preparedness for provision of marketing authorization of human pandemic influenza vaccines in non-vaccine-producing countries, TRS 1004, Annex 7
WHO biosafety risk assessment and guidelines for the production and quality control of human influenza pandemic vaccines, WHO Technical Report No. 941, 2007, Annex 5
H1N1 specific-update of TRS 941, Annex 5
AS OF 23 MAY: Update of Biosafety guidelines for the production and quality control of human influenza
Due to the need for formulations that match the currently circulating influenza strains, candidate-vaccine viruses (production viruses) matching those recommended for inclusion in seasonal and pandemic vaccines are produced and distributed on demand to qualified institutions by the WHO Collaborating Centers for Reference and Research on influenza.
Reference antigens and antiserum reagents for the standardization of vaccines are produced by several laboratories. These are not established as WHO reference materials by the Expert Committee on Biological Standardization (ECBS) due to time constraints.
Generic protocol for the calibration of seasonal/pandemic influenza antigen working reagents by WHO Essential Regulatory Laboratories
This document provides a generic protocol for the calibration of influenza antigen working reagents by the four WHO Essential Regulatory Laboratories (ERLs). It represents the consensus of the ERLs on the process of assigning a potency value to a newly established influenza antigen reagent for use in potency testing of inactivated influenza vaccines. An influenza antigen working (or reference) reagent is a preparation of inactivated whole virus that has been freeze-dried and calibrated as outlined in this document.
The calibration process involves the preparation of a primary liquid standard (PLS) and a large batch of freeze-dried antigen by one of the ERLs. The PLS is distributed to all other ERLs for independent calibration. Samples of the freeze-dried antigen are also distributed to the other ERLs and are calibrated against the PLS using SRD.
Executive summary of WHO consusltation on influenza vaccines for pregnant and lactating women: Clinical data requirements for product labelling.
Executive Summary: WHO working group meeting on Labelling information of influenza vaccines intended to be used in pregnant women, 24-25 September 2015, Geneva, Switzerland
Executive Summary: WHO informal consultation on labelling information of influenza vaccines intended to be used in pregnant women, 4-5 April 2016, Geneva, Switzerland
Essential Regulatory Laboratories (ERL)
- Center for Biologics Evaluation and Research (CBER), USA
- National Institute for Biological Standards and Control (NIBSC), UK
- National Institute for Infectious Disease (NIID), Japan
- Therapeutic Goods Administration (TGA), Australia.
Prequalified influenza vaccines
Influenza vaccines, both pandemic and seasonal, are prequalified for procurement by UN organizations:
- WHO position paper on influenza
- Pandemic (H1N1) 2009
- Epidemic and pandemic alert and response
- Global pandemic influenza action plan to increase vaccine supply
- WHO influenza fact sheet
- Global Advisory Committee on Vaccine Safety
- Vaccine Research and Development